Abstract
Methylophiopogonanone A (MO-A), a homoisoflavonoid extracted from Ophiopogon japonicus, has been shown to attenuate myocardial apoptosis and improve cerebral ischemia/reperfusion injury. However, the hypolipidemic effects remain unknown. This study was performed to investigate a potential hypolipidemic effect of MO-A in hyperlipidemia rats, as well as its underlying mechanism of action. A rat model of hyperlipidemia was induced by a high-fat diet (HFD). Animals were randomly divided into three groups (n=8/group): normal control group (NC), HFD group, and HFD+MO-A (10 mg·kg-1·d-1) treatment group. The effects of MO-A on serum lipids, body weight, activity of lipoprotein metabolism enzyme, and gene expression of lipid metabolism were evaluated in HFD-induced rats. In HFD-induced rats, pretreatment with MO-A decreased the body weight gain and reduced serum and hepatic lipid levels. In addition, pretreatment with MO-A improved the activities of lipoprotein lipase and hepatic lipase in serum and liver, down-regulated mRNA expression of acetyl CoA carboxylase and sterol regulatory element-binding protein 1c, and up-regulated mRNA expression of low-density lipoprotein receptor and peroxisome proliferator-activated receptor α in the liver. Our results indicated that MO-A showed strong ability to ameliorate the hyperlipidemia in HFD-induced rats. MO-A might be a potential candidate for prevention of overweight and dyslipidemia induced by HFD.
Highlights
Hyperlipidemia is a lipid metabolic disorder disease, which is considered the major pathogenic factor for progression and development of cardiovascular diseases, such as myocardial infarction, cerebrovascular diseases, stroke, diabetes mellitus, and atherosclerosis [1]
Bioactive ingredients derived from herbal medicines are considered efficient therapies to alleviate lipid metabolic disorder diseases because they have a high potency against dyslipidemia with few adverse effects [6]
All rats were fed with standard chow for seven days to adapt to the laboratory environment and randomly separated into three groups according to body weight: normal control group (NC), high-fat diet (HFD), and HFD+Methylophiopogonanone A (MO-A)
Summary
Hyperlipidemia is a lipid metabolic disorder disease, which is considered the major pathogenic factor for progression and development of cardiovascular diseases, such as myocardial infarction, cerebrovascular diseases, stroke, diabetes mellitus, and atherosclerosis [1]. It is a group of disorders characterized by increased triglycerides, high cholesterol and plasma lipid levels, and usually coexists with obesity [2]. Bioactive ingredients derived from herbal medicines are considered efficient therapies to alleviate lipid metabolic disorder diseases because they have a high potency against dyslipidemia with few adverse effects [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
